Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A manifestation of von Hippel-Lindau disease or other familial renal cell cancer syndromes that present as a malignant epithelial neoplasm of the kidney. It is characterized by the presence of lipid-containing clear cells within a vascular network. The tumor usually is bilateral and polycentric, and metastasizes to unusual sites. Late metastasis is common.
Biomarker and diagnostic research for hereditary clear cell renal cell carcinoma has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for hereditary clear cell renal cell carcinoma.
172 publications have been identified in PubMed for hereditary clear cell renal cell carcinoma. Kisho has analyzed 125 by research type. Research spans Review / Meta-Analysis (38%), Case Report / Case Series (24%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 48 | 38% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:25 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
30 |
24% |
Disease patterns and progression | 13 | 10% |
Laboratory research | 12 | 10% |
Testing and diagnosis research | 11 | 9% |
Clinical study results | 6 | 5% |
New treatment approaches | 5 | 4% |
Mai X (2026). [PMID: 41779387](https://pubmed.ncbi.nlm.nih.gov/41779387/). *JAMA Dermatol*. [Review / Meta-Analysis]
van den Berg NI (2026). [PMID: 41895278](https://pubmed.ncbi.nlm.nih.gov/41895278/). *Cancer Cell*. [Review / Meta-Analysis]
Yuska T (2026). [PMID: 41631080](https://pubmed.ncbi.nlm.nih.gov/41631080/). *Cureus*. [Case Report / Case Series]
Valdés Vásquez JF (2026). [PMID: 42118473](https://pubmed.ncbi.nlm.nih.gov/42118473/). *Int Urol Nephrol*. [Review / Meta-Analysis]
Tashiro K (2026). [PMID: 41589252](https://pubmed.ncbi.nlm.nih.gov/41589252/). *Int Cancer Conf J*. [Clinical Trial Publication]
Masuda H (2026). [PMID: 40652926](https://pubmed.ncbi.nlm.nih.gov/40652926/). *Urol Int*. [Case Report / Case Series]
Udupa M (2026). [PMID: 41554543](https://pubmed.ncbi.nlm.nih.gov/41554543/). *CMAJ*. [Case Report / Case Series]
Hoffman TL (2026). [PMID: 42120995](https://pubmed.ncbi.nlm.nih.gov/42120995/). *Hered Cancer Clin Pract*. [Clinical Trial Publication]
Lewis K (2026). [PMID: 41505197](https://pubmed.ncbi.nlm.nih.gov/41505197/). *Urol Pract*. [Diagnostic / Biomarker]
Fanelli GN (2026). [PMID: 41634405](https://pubmed.ncbi.nlm.nih.gov/41634405/). *Virchows Arch*. [Diagnostic / Biomarker]
AI-curated news mentioning hereditary clear cell renal cell carcinoma
Updated Aug 28, 2026
A rare case study highlights tumor-to-tumor metastasis, where clear cell renal cell carcinoma metastasizes into lung adenocarcinoma. This finding contributes to the understanding of cancer behavior and potential treatment implications.
A study highlights the use of tumor-informed ctDNA surveillance for early detection of molecular residual disease in patients with clear cell renal cell carcinoma following radical nephrectomy and IVC thrombectomy. This approach may enhance monitoring and treatment strategies for this cancer type.